within Pharmacolibrary.Drugs.ATC.L;

model L01EA02
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.142,
    Cl             = 0.0030833333333333333,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 2.5,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0195,
    Tlag           = 14.399999999999999,            
    Vdp             = 1.69,
    k12             = 63,
    k21             = 63
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01EA02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Dasatinib is an oral tyrosine kinase inhibitor used in the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It is approved for use in adults and children and acts by inhibiting BCR-ABL and other kinases.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters observed in adult patients with chronic myeloid leukemia (CML) after oral administration.</p><h4>References</h4><ol><li><p>Levêque, D, et al., &amp; Natarajan-Amé, S (2020). Clinical Pharmacokinetics and Pharmacodynamics of Dasatinib. <i>Clinical pharmacokinetics</i> 59(7) 849–856. DOI:<a href=&quot;https://doi.org/10.1007/s40262-020-00872-4&quot;>10.1007/s40262-020-00872-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32112275/&quot;>https://pubmed.ncbi.nlm.nih.gov/32112275</a></p></li><li><p>Raish, M, et al., &amp; Mohammed, OM (2024). Pharmacokinetics of Dasatinib in Rats: a Potential Food-Drug Interaction with Naringenin. <i>European journal of drug metabolism and pharmacokinetics</i> 49(2) 239–247. DOI:<a href=&quot;https://doi.org/10.1007/s13318-024-00881-9&quot;>10.1007/s13318-024-00881-9</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38376657/&quot;>https://pubmed.ncbi.nlm.nih.gov/38376657</a></p></li><li><p>Hofmann, J, et al., &amp; Slanař, O (2023). Dasatinib anhydrate containing oral formulation improves variability and bioavailability in humans. <i>Leukemia</i> 37(12) 2486–2492. DOI:<a href=&quot;https://doi.org/10.1038/s41375-023-02045-1&quot;>10.1038/s41375-023-02045-1</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37789147/&quot;>https://pubmed.ncbi.nlm.nih.gov/37789147</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01EA02;
